The maker of blockbuster weight-loss drug Wegovy will cut 9,000 jobs, about 11.5 per cent of its workforce, in a restructure to save some $1.3 billion (£926 million) annually.
Novo Nordisk, which was at one point last year Europe's most valuable listed company, is facing a pivotal moment as Wegovy and its diabetes treatments Ozempic lose market share and sales growth slows, especially in the United States.
